DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Rob Arnold’s career as a strategy consultant has spanned more than 25 years. During this time he has directed engagements throughout Europe, North America, and Asia, developing creative solutions to some of the most challenging business situations in Life Sciences.

 

Rob has supported some of the world’s largest companies in their strategies for the health market, including their most critical decisions about acquisitions, divestitures, technology, and geographic focus.

 

Rob pioneered decision-analysis-based quantitative techniques that helped Life Sciences clients in a number of areas from probabilistic/scenario-based forecasting to modeling complex R&D and in market portfolios.

 

While at Strategic Decision Group, Rob led the Life Sciences team, developing portfolio management and resource allocation processes and methodologies, based on Stanford University research, for the world’s leading pharma companies.

 

Rob co-authored the ‘Portfolio Management and Resource Allocation’ article published in the Harvard Business Review of 1998, one of the most requested reprints from HBR, even today.

 

He applied the principles of portfolio management to support nine of the ten largest pharma companies and has gone on to work with countless other smaller companies in the biotech, devices, and pharma businesses across the world.

 

Rob was a Vice President with IMS for six years, following their acquisition of SDG’s Life Sciences practice. He was with SDG for 22 years, the last five as CEO.

 

Mr. Arnold holds an MBA from the Amos Tuck School of Dartmouth College and an MA from Cambridge University.